Roth Capital Maintains Buy on OptimizeRx, Lowers Price Target to $18
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $32 to $18.
Roth Capital analyst Richard Baldry maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $32 to $18.